依达拉奉对不稳定型心绞痛血清超敏C反应蛋白的影响  

Effect of Edaravone on Serum High-sensitivity C-reactive Protein in Patients with Unstable Angina

作　　者：鲁锋[1] 刘涛[1] 

机构地区：[1]南京医科大学附属淮安一院,江苏省淮安市223002

出　　处：《实用心脑肺血管病杂志》2014年第1期66-67,共2页Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease

摘　　要：目的观察依达拉奉对不稳定型心绞痛(UA)患者血清超敏C反应蛋白(hs-CRP)水平的影响。方法选择2008—2011年在我院确诊的UA患者88例,将其随机分为对照组和依达拉奉治疗组。对照组给予常规治疗,依达拉奉治疗组在此基础上给予依达拉奉,观察两组治疗前后血清hs-CRP水平及4周内恶性心脏事件发生情况。结果治疗7 d、14 d后依达拉奉治疗组血清hs-CRP水平低于对照组(P<0.05),4周内依达拉奉治疗组恶性心脏事件发生率低于对照组(P<0.05)。结论依达拉奉治疗UA,可以降低患者血清hs-CRP水平,有助于减少恶性心脏事件的发生。Objective To observe the effect of edaravone on serum high - sensitivity C - reactive protein （ hs - CPR） level in patients with unstable angina （UA）. Methods 88 patients with UA in our hospital were chosen from 2010 to 2011, they were randomly divided into control group and treatment group. Patients in the control group were given conventional treat- ment, while patients in ~he treatment group given edaravone. The serum hs - CRP level of two groups were detected before and after treatment, and incidence of malignant heart events in 4 weeks recorded. Results The serum hs - CRP levels of the treat- ment group were lower than those of control group 7 d, 14 d after treatment （ P 〈 0.05 ） , and incidence of malignant heart events lower （P 〈 0.05）. Conclusion Edaravone can reduce the level of hs - CRP, help to reduce the incidence of malignant heart events in patients with UA.

关 键 词：依达拉奉 心绞痛 不稳定型 C反应蛋白质 

分 类 号：R541.42[医药卫生—心血管疾病]